Figure 1A. Efficacy Outcomes Stratified by Baseline LDL-C HR Primary Composite Endpoint (95°/o Cl} Pinteraction • 0.85 (0.79-0.92) All Patients Baseline LDL-C <70 mg/dL 0.80 (0.60-1.07) 0.65 I 0 mg/dl Baseline LDL-C 2:70 0.86 (0.79-0.92) I I 1.0 2.5 0.4 Secondary Composite Endpoint I I All Patients 0.80 (0.73-0.88) I Baseline LDL-C <70 mg/dL I 0.70 (0.48-1.01) mg/dl I Baseline LDL-C 2:70 0.81 (0.73-0.89) 0.44 OA 1D 2.5 Evolocumab better Placebo better
Figure 1A. Efficacy Outcomes Stratified by Baseline LDL-C Primary Composite Endpoint All Patients • Baseline LDL-C <70 mg/dL I Baseline LDL-C 2:70 mg/dl 0 I I HR (95°/o Cl} 0.85 (0.79-0.92) 0.80 (0.60-1.07) 0.86 (0.79-0.92) Pinteraction 0.65 0.4 1.0 2.5 Secondary Composite Endpoint All Patients I I 0.80 (0.73-0.88) Baseline LDL-C <70 mg/dL Baseline LDL-C 2:70 mg/dl 0.70 (0.48-1.01) I 0.81 (0.73-0.89) I I 0.44 OA 1D 2.5 Evolocumab better Placebo better